NewsPress Releases | Media Coverage
Non-opioid pain therapeutics company Regulonix Raises $2 Million in Seed Funding Led by UAVenture Capital Fund
Regulonix, LLC, a University of Arizona biotechnology start-up company focused on developing non-opioid therapeutics to relieve chronic pain, today announced seed investment of $2 million. Read the press release here.
Regulonix Licenses Non-Opioid Pain Drug Candidates
Regulonix has invented and licensed a new class of non-opioid compounds that have been shown in animal models to be more effective than morphine, non-addictive, and non-toxic. Congratulations to Rajesh Khanna, May Khanna, and Vijay Gokhale at the University of Arizona College of Medicine, Tucson. Full story here.
Arizona Daily Star business and technology news
A new, early stage venture capital firm aimed at supporting University of Arizona technology spinoffs has made its first three investments. Read more.
Tech Launch Arizona highlights first local venture capital fund investments
UAVenture Capital Fund LLC, the Tucson-based early-stage capital fund dedicated to the commercialization of University of Arizona science and technology, has announced its first three portfolio investments. Read more.
Regulonix Featured in Tucson Tech
A recent article in the Arizona Daily Star details the successes and future plans of Tech Launch Arizona. TLA is in its 5th year of supporting start-ups at the University of Arizona. Regulonix is featured in the article here.
San Diego Showcase
Look for Regulonix at the San Diego Innovation Showcase October 26, 2017
Phase I Funding
Regulonix has received a 12-month Phase I STTR grant from the National Institutes of Health for “Regulators of NaV1.7 Channels: Novel Anti-Allodynic Drug Candidates”